Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-07-01 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of regulatory approval from the Central Drugs Standard Control Organisation for an additional indication of a pharmaceutical product. The content is an announcement of a material event or information relevant to the stock exchanges and investors, rather than a financial report or detailed filing. The document length is short (1830 characters) and it does not contain financial data, earnings, management discussion, or audit information. It is an intimation or disclosure under regulatory requirements, fitting best under Regulatory Filings (RNS).
2025-07-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of regulatory approval from the Central Drugs Standard Control Organisation for an additional indication of a pharmaceutical product. The content is an official announcement of a material event related to the company, AstraZeneca Pharma India Limited. The document is short (1830 characters) and does not contain financial data, financial statements, or detailed analysis. It is an intimation or regulatory announcement about a business development rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-01 English
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI Listing Obligations and Disclosure Requirements. It is a regulatory compliance notification rather than a financial report or announcement of results. The document is short (1512 characters) and does not contain financial data or detailed report content. It is an official regulatory filing informing the exchanges about authorized contacts for materiality determination, fitting the Regulatory Filings (RNS) category as a general compliance announcement.
2025-07-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI Listing Obligations and Disclosure Requirements. It is a regulatory compliance communication rather than a financial report, announcement of voting results, or management change. The document is short (1512 characters) and does not contain financial data or report content. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2025-07-01 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It mentions the enclosure of a certificate from the Registrar and Transfer Agents confirming compliance with a regulatory requirement. The document is short (1403 characters) and primarily serves as a submission or attestation of compliance rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. This fits the profile of a regulatory filing or compliance certificate submission rather than a full report or announcement of financial results. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-06-20 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings
2025-06-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.